Arrowstreet Capital Limited Partnership Has $21.12 Million Holdings in Henry Schein, Inc. $HSIC

Arrowstreet Capital Limited Partnership grew its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 80.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 289,051 shares of the company’s stock after purchasing an additional 129,077 shares during the period. Arrowstreet Capital Limited Partnership owned about 0.24% of Henry Schein worth $21,115,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cetera Investment Advisers grew its position in Henry Schein by 14.7% during the first quarter. Cetera Investment Advisers now owns 4,924 shares of the company’s stock worth $337,000 after buying an additional 630 shares in the last quarter. Federated Hermes Inc. raised its holdings in Henry Schein by 766.5% in the 1st quarter. Federated Hermes Inc. now owns 2,045 shares of the company’s stock valued at $140,000 after acquiring an additional 1,809 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of Henry Schein by 18.3% during the 1st quarter. XTX Topco Ltd now owns 5,066 shares of the company’s stock worth $347,000 after purchasing an additional 785 shares in the last quarter. Natixis Advisors LLC grew its holdings in shares of Henry Schein by 5.2% during the 1st quarter. Natixis Advisors LLC now owns 11,508 shares of the company’s stock worth $788,000 after purchasing an additional 572 shares in the last quarter. Finally, Blair William & Co. IL increased its position in shares of Henry Schein by 33.1% during the first quarter. Blair William & Co. IL now owns 9,194 shares of the company’s stock valued at $630,000 after purchasing an additional 2,288 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 0.4%

HSIC stock opened at $73.62 on Monday. The business has a fifty day moving average price of $68.30 and a 200 day moving average price of $69.42. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.40 and a quick ratio of 0.79. Henry Schein, Inc. has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The stock has a market capitalization of $8.67 billion, a price-to-earnings ratio of 23.30, a P/E/G ratio of 2.26 and a beta of 0.89.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The company had revenue of $3.34 billion for the quarter, compared to analyst estimates of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HSIC has been the subject of several research reports. Morgan Stanley raised their target price on Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company lifted their target price on shares of Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $76.17.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.